Today's Veterinary Practice

SEP-OCT 2015

Today's Veterinary Practice provides comprehensive information to keep every small animal practitioner up to date on companion animal medicine and surgery as well as practice building and management.

Issue link: http://todaysveterinarypractice.epubxp.com/i/561362

Contents of this Issue

Navigation

Page 37 of 83

Today's VeTerinary PracTice | september/october 2015 | tvpjournal.com canine PediaTrics: The VomiTing PuPPy Peer reviewed 36 vomiting abated). A potent antiemetic was initiated to treat nausea and minimize risk for aspiration pneumonia. The supportive medications and nutrition JP received are outlined in Table 4 ; daily in-hospital monitoring for parvovirus patients is described in Table 5 . Ongoing Supportive Care JP's vital parameters improved markedly over the frst few hours of therapy. By the following day, he subjectively looked less nauseated and had less abdominal pain. A temporary nasogastric feeding tube was placed at that time for nutritional support, with sporadic gastric suctioning to measure Other Therapeutic Options: Worth It? In the past, fresh or fresh frozen plasma from recovered dogs had been suggested to provide antiparvoviral antibodies. Recent studies, however, have demonstrated no benefcial effect of this method and shown that even recently recovered animals have minimal anti-canine parvovirus antibody concentrations. 8,9 Moreover, such treatment may prime the dog for future transfusion reactions later in life. Equine endotoxin antiserum, recombinant human granulocyte-stimulating factor, and antiviral agents (eg, oseltamivir) have not been shown to improve survival or outcome. 10-12 In small studies, use of feline interferon has been weakly associated with improved survival; however, this agent is not readily available in veterinary hospitals in the U.S. 13,14 Table 4. Supportive Therapy for JP ThERaPY TYPE MEDiCaTioN/DiET DoSaGE Antiemetic Maropitant 1 mg/kg SC or IV Q 24 H Gastroprotectant Famotidine 0.5 mg/kg IV Q 12 H Antibiotic Ampicillin/sulbactam 25 mg/kg IV Q 8 H Antidiarrheal Probiotics Dependent on probiotic chosen Analgesics Buprenorphine 0.02 mg/kg IV Q 8 H PRN Lidocaine 20 mcg/kg/min IV CRI Nutrition Clinicare (abbottanimalhealth.com) RER/24 H = mLs of Clinicare per H via nasogastric tube CRI = constant rate infusion; PRN = as needed; RER = resting energy requirement Table 5. Daily Monitoring Recommended for Parvovirus Patients ThERaPY SPECiFiCS FREQUENCY a Physical examination Temperature, heart rate, respiratory rate, lung auscultation, pulse quality, mucous membrane color, capillary refll time, abdominal pain, urine output Q 4 to 6 H b Monitoring Packed cell volume, total solids, blood glucose Q 6 to 8 H b Blood monitoring Electrolytes, especially potassium Q 24 H Blood pressure Q 6 to 8 H b Pulse oximetry Dependent on clinical signs Nursing care & barrier treatment For example, zinc oxide Q 2 H, depending on severity of diarrhea Nutritional evaluation Gastric residual volume, tolerance of nasoesophageal or nasogastric tube feeding Q 2 to 4 H a. Dependent on severity of clinical signs b. These parameters may need to be monitored more frequently, even Q 1 H, in some very critical or dynamic patients.

Articles in this issue

Links on this page

Archives of this issue

view archives of Today's Veterinary Practice - SEP-OCT 2015